No Data
No Data
Short Interest Surges to 21.83% as Coherus BioSciences, Inc. (CHRS) Faces Revenue Challenges
Institutional Owners May Take Dramatic Actions as Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Recent 12% Drop Adds to One-year Losses
Baird Maintains Coherus BioSciences(CHRS.US) With Buy Rating, Maintains Target Price $8
Baird analyst Colleen M. Kusy maintains $Coherus BioSciences(CHRS.US)$ with a buy rating, and maintains the target price at $8.According to TipRanks data, the analyst has a success rate of 34.8% and
Top Midday Decliners
HC Wainwright & Co. Reiterates Buy on Coherus BioSciences, Maintains $12 Price Target
Truist Financial Maintains Coherus BioSciences(CHRS.US) With Buy Rating
Truist Financial analyst Srikripa Devarakonda maintains $Coherus BioSciences(CHRS.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 58.4% and a total average